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Objectives This study describes the 5-year efficacy of catheter ablation for long-standing persistent atrial fibrillation (LS-AF).
Background Long-term outcome data after catheter ablation for LS-AF are limited.
Methods Long-term follow-up of 56 months (range 49 to 67 months) was performed in 202 patients (age 61  9 years)
who underwent the sequential ablation strategy for symptomatic LS-AF. Initial ablation strategy was circumfer-
ential pulmonary vein isolation (PVI). Additional ablation was performed only in acute PVI nonresponder, if direct
current cardioversion failed after PVI.
Results After the first ablation procedure, sinus rhythm was documented in 41 of 202 (20.3%) patients. After multiple
procedures, sinus rhythm was maintained in 91 of 202 (45.0%) patients, including 24 patients receiving antiar-
rhythmic drugs. In 105 patients, PVI was the sole ablative therapy, 49 (46.7%) of those patients remained in
sinus rhythm during follow-up. Patients with a total AF duration of 2 years had a significantly higher ablation
success rate than patients whose AF duration was 2 years (76.5% vs. 42.2%, respectively; p  0.033). Persis-
tent AF duration (hazard ratio: 1.09 [95% confidence interval: 1.04 to 1.13]; p  0.001) independently predicted
arrhythmia recurrences, and acute PVI responders had a reduced risk of relapse (hazard ratio: 0.57 [95% confi-
dence interval: 0.41 to 0.78]; p  0.001) after the first ablation.
Conclusions During 5-year follow-up, single- and multiple ablation procedure success was 20% and 45%, respectively, for pa-
tients with LS-AF. For patients with a total AF duration of 2 years, the outcomes were favorable. (J Am Coll
Cardiol 2012;60:1921–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.060Pulmonary vein isolation (PVI) is a well-established treatment
option in patients with atrial fibrillation (AF). In long-term
follow-up of as long as 5 years, themultiple procedure success rate
is approximately 80% in patients with paroxysmal AF (PAF)
(1–3). However, recurrences are frequent, and repeat ablation is
often required to maintain freedom from AF (1–3).
Current guidelines from HRS/EHRA/ECAS state that:
1) ablation strategies that target the PVs and/or PV antrum
should form the cornerstone for most AF ablation proce-
dures; and 2) if the PVs are targeted, complete electrical
isolation should be the goal (1). However, in patients with
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accepted April 24, 2012.long-standing persistent AF (LS-AF), PVI alone may not
be sufficient as outcomes after PVI alone are disappointing,
with success rates ranging from 36% to 56% at medium
term follow-up (2–5). To improve outcomes in patients
with LS-AF, various ablation strategies in addition to PVI
have been described. The most widely used additional
See page 1930
ablation strategy is the ablation of complex fractionated
atrial electrograms (CFAE) (6,7). However, numerous gaps
in our knowledge remain such as the adjunctive benefit of
these techniques and the long-term efficacy of LS-AF
ablation in general. Until recently, long-term outcome data
of 2 years’ follow-up after catheter ablation for LS-AF
have been sparse (8).
We previously evaluated the short-term outcomes of catheter
ablation for LS-AF (5). In this study, we present long-term
follow-up data from the same cohort. The objectives of this study
were to determine: 1) the long-term efficacy of the sequential
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5-Year Outcomes After Long-Standing-AF Ablation November 6, 2012:1921–9ablation strategy for treatment of
LS-AF; 2) the regression of LS-AF
toward PAF after ablation; and
3) predictors of recurrence.
Methods
Study population. Two hun-
dred and five patients were con-
secutively enrolled in the initial
study. The study population and
methods have been published
previously (5). Three patients
were lost to follow-up. Long-
term follow-up and data analysis
were performed for the remain-
ing 202 patients (age 61  9
years). All patients had symp-
tomatic LS-AF refractory to an-
tiarrhythmic drugs (AAD) and
underwent radiofrequency cur-
rent catheter ablation at our in-
stitution between November
003 and July 2007. The LS-AF was defined as continuous
F of 1 year duration (9). Baseline characteristics of the
atient population are presented in Table 1. Total AF
uration was 99 64 months (median 84 months [range 60
to 120 months]), duration of continuous AF (persistent AF)
was 49  44 (median 36 months [range 20 to 60 months]).
linical follow-up was completed in March 2011.
lectrophysiological study. After written informed con-
ent, all patients underwent a transesophageal echocardio-
ram before the procedure. Oral anticoagulation (OAC)
herapy was stopped at least 3 days before ablation and
eplaced with low-molecular-weight heparin. The proce-
ure was performed under deep sedation utilizing midazo-
am, fentanyl, and a continuous infusion of propofol. Two
tandard catheters were positioned at the His bundle region
nd inside the coronary sinus. Two or 3 SL1 sheaths (St.
ude Medical, Minneapolis, Minnesota) were advanced to
he left atrium (LA) using a modified Brockenbrough
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
AT  atrial tachycardia
CFAE  complex
fractionated atrial
electrograms
CI  confidence interval
HR  hazard ratio
LA  left atrium
LS-AF  long-standing
persistent atrial fibrillation
OAC  oral anticoagulation
PAF  paroxysmal atrial
fibrillation
PV  pulmonary vein
PVI  pulmonary vein
isolation
SR  sinus rhythm
Baseline Patient Characteristics (N  202)Table 1 Baseline Patient Characteristics (N  202)
Age, yrs 61 9
Male 160 (79)
Total AF duration, months 99 64
Persistent AF duration, months 49 44
Patients treated with amiodarone 115 (57)
Structural heart disease 32 (16)
LA diameter, mm 49 6
Hypertension 155 (77)
LVEF, % 60 7a
Values are mean  SD or n (%).
AF  atrial fibrillation; LA  left atrial; LVEF  left ventricular ejection fraction.echnique. After transseptal catheterization, intravenous
eparin was administered, targeting an activated clotting
ime of 250 s to 300 s. Transseptal sheaths were continu-
usly flushed with heparinized saline. Three-dimensional
lectroanatomical LA reconstruction using the CARTO
ystem (Biosense Webster, Diamond Bar, California) and
blation were performed using a 3.5-mm tip catheter
ThermoCool Navi-Star, Biosense Webster) (10).
blation protocol during the initial procedure. All pa-
ients underwent circumferential PVI using irrigated radio-
requency current, as previously published (Fig. 1) (11).
uring PVI, 1 or 2 spiral mapping catheters (Lasso,
iosense Webster) were positioned inside the ipsilateral
Vs. The endpoint of PVI was defined as the absence of any
V spike potential recorded on either Lasso catheter for at
east 30 min after PVI. If after PVI, AF did not convert to
inus rhythm (SR) or atrial tachycardia (AT), up to 3
iphasic direct current shocks (200 J, 360 J, and 360 J) were
dministered aiming at restoration of SR. Defibrillator
atches were positioned in an anterior-posterior position. If
F was reinduced by a non-PV trigger during the 30-min
aiting period, the AF trigger was targeted for ablation but
o CFAE ablation was performed. The CFAE ablation was
nly performed if SR could not be achieved at all. No
edications or pacing maneuvers were used at that point. If
C cardioversion was successful, patients were defined as
cute PVI responder (Fig. 1). The CFAE ablation was
erformed, as described before, in an attempt to convert AF
o SR or AT (5). Termination was defined as transition
irectly from AF to SR or by 1 or multiple ATs (8). The
FAEs were analyzed visually and were defined as pub-
ished by Nademanee et al. (6): 1) fractionated electrograms
omposed of1 deflections and/or continuous deflection of
prolonged activation complex; and 2) atrial electrograms
ith 120 ms CL recorded over a 5-s recording period.
During ablation of CFAEs or LA linear lesions, the Lasso
atheter was positioned in the left atrial appendage (LAA) to
ontinuously record LAA activity. Only in the presence of a
macro) AT were linear lesions applied. Electrophysiological
vidence of bidirectional block was validated in SR (12).
uperior vena cava isolation was attempted only if spontaneous
ocal-discharge was demonstrated from this location. Patients
equiring ablation strategies in addition to PVI were defined as
cute PVI nonresponder.
blation protocol during repeat procedure. Repeated
lectrophysiology procedures were undertaken for recurrent
trial tachyarrhythmias (ATa). The initial strategy was an
ssessment of PV reconduction, followed by closure of all
V conduction gaps and electrical reisolation. Ablation of
FAEs was only performed in a PVI nonresponder if:
) DC cardioversion failed after repeat PVI; or 2) patients
emonstrated no PV reconduction (5). In patients with no
V reconduction presenting in SR, AF was induced by
urst stimulation from the LAA before CFAE ablation.
ost-ablation treatment and follow-up. The OAC ther-
py was started immediately post-procedure, targeting an
1923JACC Vol. 60, No. 19, 2012 Tilz et al.
November 6, 2012:1921–9 5-Year Outcomes After Long-Standing-AF Ablationinternational normalized ratio of 2 to 3. Where the LAA
was isolated, lifelong OAC therapy was recommended.
In all other patients, OAC therapy was continued for at
least 3 months. Thereafter, indication for anticoagulation
therapy was solely based on the patient’s CHADS2
(congestive heart failure, hypertension, age 75 years,
diabetes mellitus, and prior stroke or transient ischemic
attack) score (9). Before discharge, a 24-h Holter record-
ing and echocardiographic evaluation was performed.
Discontinuation of AADs was recommended 3 months
after ablation. A transthoracic echocardiogram, 12-lead
electrocardiogram, and 24-h Holter recording were ob-
tained at our outpatient clinic or by the referring physi-
cian 1, 3, and 6 months after ablation and thereafter at
6-month intervals.
Recurrence was defined as episodes of AF or AT lasting
Figure 1 Ablation Study Protocol
Ablation study protocol at (A) the first ablation procedure and (B) the repeat ablat
CFAE  complex fractionated atrial electrogram; DC  direct current; PV  pu30 s as documented by 12-lead electrocardiogram orHolter monitoring. This study did not adhere to a pre-
defined blanking period. Clinical success was defined as
freedom from recurrence during the entire follow-up period.
Regression of persistent AF was defined as change from
LS-AF to PAF or maintenance of SR on AAD after
arrhythmia recurrence.
Statistical analysis. Categorical variables are expressed as
absolute and relative frequencies. Continuous variables are
expressed as mean  SD or median and interquartile range
as appropriate. Group mean differences were examined by
the Student’s t test for independent samples. Differences in
categorical variables between groups were compared by the
chi-square test of significance. Event-free survival were
estimated by the method of Kaplan-Meier and compared by
the log-rank test. Predictors of arrhythmia recurrence were
performed using Cox proportional hazards regression
ocedure. AF  atrial fibrillation; AT  atrial tachycardia;
ry vein; PVI  pulmonary vein isolation; SR  sinus rhythm.ion pr
lmonamodels.
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5-Year Outcomes After Long-Standing-AF Ablation November 6, 2012:1921–9The following variables were used as exploratory variables
in univariate and multiple survival prediction models: age,
sex, total AF duration, persistent AF duration, amiodarone,
structural heart disease, coronary artery disease, LA diam-
eter, hypertension, left ventricular ejection fraction,
CHADS2 score, procedure duration, fluoroscopy duration,
termination, complications, and PVI as the sole ablation
strategy. Variables that were univariately associated with
survival (p  0.2) were considered for a multiple survival
prediction model.
The multivariate prediction models for time to recurrence
after the index procedure and after the final ablation
procedure were performed by stepwise regression based on
likelihood ratios. For each variable, hazard ratio (HR), 95%
confidence interval (CI), and Wald test p values of the final
model are displayed. A HR of 1 indicates a reduced
likelihood of relapse for increasing values of the variable. A
2-tailed probability value of  0.05 was deemed significant.
he authors had full access to and take full responsibility for
he integrity of the data. All authors have read and agreed to
he manuscript as written.
esults
linical outcomes after a single procedure. During a
edian follow-up of 56 months (range 49 to 67 months),
R was maintained in 41 of 202 (20.3%) patients (Figs. 2
nd 3). Recurrent arrhythmia after the index procedure was
ersistent AF in 103 of 202 (51.0%) patients, PAF in 27 of
02 (13.4%) patients, and AT in 31 of 202 (15.3%) patients
Fig. 2). Regression of AF occurred in 36 of 202 (17.8%)
atients (16 patients maintained SR after the reinitiation of
ADs, and 20 patients regressed to PAF). Arrhythmia
ecurred within the first year after ablation in 13 of 202
64.4%) patients. Thirty-one (15.3%) patients had recur-
ences after 12 months including 10 (5.0%) patients with
ecurrences 3 years after ablation.
linical outcomes after the last procedure. During a
edian follow-up of 50 months (range 36 to 61 months), 91
f 202 (45.0%) patients remained in SR, including 24
atients taking AADs (amiodarone in 2 patients). Regres-
ion of AF was noted in 47 (23.3%) patients (36 patients
aintained SR after reinitiation of AADs, and 11 patients
hanged to PAF). Recurrent arrhythmia was persistent AF
n 65 (58.6%) patients, AT in 19 (17.1%), and PAF in 27
24.3%).
ummary of ablation procedures. Procedural details are
ummarized in Table 2. A total of 383 procedures were
erformed in 202 patients (median 2, range 1 to 5). PVI was
erformed in all 202 patients and was the sole ablative
trategy in 105 (52.0%) patients by the final procedure.
Recovered PV conduction was found in 97 of 126
77.0%) patients at the first, 12 of 42 (28.6%) at the second,
nd no (0%) patient at the third or fourth redo procedures.
hree patients at the first redo procedure and 1 patient at
he second redo procedure presented in SR without PV teconduction, therefore requiring AF induction before
FAE ablation.
Isolation of LAA occurred in 10 of 97 (10.3%) patients
ndergoing PVI and additional ablation (acute PVI nonre-
ponder): this affected no patient during the first, 4 patients
uring the second, 3 during the third, and 3 at the fourth
rocedure.
The following complications occurred in 18 (4.7%) of 383
rocedures: ischemic stroke (n  2), transient ischemic
ttack (n  1), femoral hematoma requiring blood transfu-
ion (n  11) and vascular surgery (n  3 of 11),
neumothorax (n  1), aspiration pneumonia (n  1),
ransient pulmonary edema (n  1), and cardiac tamponade
n  1).
Cerebrovascular events occurred during follow-up as fol-
ows: cerebral hemorrhage (n  1), stroke (n  9), and
Figure 2 Flowchart Demonstrating Arrhythmia Outcome
AT  atrial tachycardia; PAF  paroxysmal atrial fibrillation;
Pers. AF  persistent atrial fibrillation; SR  sinus rhythm.ransient ischemic attack (n  4) including 3 periprocedural
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November 6, 2012:1921–9 5-Year Outcomes After Long-Standing-AF Ablationevents as stated above. Thromboembolic events occurred in 2
patients without ATa recurrence and in 1 patient with his first
ATa episode after ablation. The latter 3 patients had
CHADS2 scores of 1, 2, and 3, respectively, and were not
eceiving OAC therapy at the time of the event.
Five deaths occurred during follow-up due to myocardial
nfarction (n  1), leukemia (n  1), non-Hodgkin’s
ymphoma (n  1), gallbladder cancer (n  1), and
nknown cause (n  1).
VI as the sole ablative strategy. At the first procedure,
65 of 202 (81.7%) patients were acute PVI responders
Tables 2, 3), and therefore received PVI as the sole ablation
trategy. Arrhythmia recurrence occurred in 132 of 165
80.0%) patients. By the last procedure, PVI was the sole
blation strategy in 105 of 202 (52.0%) patients (acute PVI
esponder).
Figure 3 Single and Multiple Procedure Outcomes
Kaplan-Meier event-free survival curve after the first procedure (blue line) and afte
Plus sign () indicates censored. Numbers at bottom indicate patients at risk
Summary of Ablation ProceduresTable 2 Summary of Ablation Procedures
Procedure PVI Only Until This Procedu
First procedure (n  202) 165 (165)
Second procedure (n  126) 0 (60)
Third procedure (n  42) 0 (5)
Fourth procedure (n  11) 0 (0)
Fifth procedure (n  2) 0 (0)
Ablation summary (last procedure) 105
Bold values indicate patients in whom this ablation strategy was performed for the first time. Valu
or in whom it was repeated.
AES  atrial extrasystoles; CFAE  complex fractionated atrial electrogram; LA  left atrial; PVI  puIn the overall population, PVI alone was able to establish
ong-term SR in 24.3% (49 of 202) of the patients and in
6.7% (49 of 105) of acute PVI responders. Regression of
F was noted in another 27 of 105 (25.7%) acute PVI
esponders (SR after readministration of AADs in 21 and
hange to PAF in 6 patients).
The only significant difference between patients who
aintained SR after PVI alone and the remaining patients
as the mean duration of persistent AF (35.2  22.5
months vs. 53.5  48.5 months; p  0.045).
Acute PVI responders at the first procedure had a
significantly lower risk for arrhythmia recurrence (HR:
0.54 [95% CI: 0.39 to 0.74]; p  0.001) than acute PVI
nonresponders. Patients undergoing PVI plus additional
ablation had a nonsignificantly higher risk for procedural
complications compared to patients undergoing PVI
ast procedure (red line).
 atrial tachyarrhythmia.
PVI and Additional Ablation
CFAE LA Line SVC/AES
29 (29) 12 (12) 7 (7)
15 (21) 24 (26) 13 (0)
15 (20) 21 (26) 1 (0)
1 (2) 3 (6) 0 (0)
0 (0) 0 (2) 0 (0)
60 60 21
rentheses indicate patients in whom this ablation strategy was performed either for the first timer the l
. ATare
es in palmonary vein isolation; SVC  superior caval vein.
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5-Year Outcomes After Long-Standing-AF Ablation November 6, 2012:1921–9alone (6.7% vs. 11.3%; p  0.244). Additionally, a 10%
incidence of LAA isolation was noted in the latter group.
Predictors of arrhythmia recurrence. After a single pro-
cedure, univariate predictors of recurrence were persistent
AF duration, total AF duration, and PVI as the sole ablative
strategy. For each additional year of persistent AF, the risk
of arrhythmia recurrence increased by 10.0% (HR: 1.10
[95% CI: 1.05 to 1.14]; p 0.001). For each additional year
of total AF duration, the risk for arrhythmia recurrence
increased by 4.9% (HR: 1.05 [95% CI: 1.01 to 1.07]; p 
0.002). PVI performed alone was associated with a signifi-
cantly reduced risk of relapse. In multivariate analyses,
persistent AF duration (HR: 1.09 [95% CI: 1.04 to 1.13];
p  0.001) and PVI as the sole ablative strategy (HR: 0.57
[95% CI: 0.41 to 0.78]; p 0.001) independently predicted
arrhythmia recurrences.
Univariate predictors of arrhythmia recurrence after the
last ablation procedure were persistent AF duration (HR:
1.07 [95% CI: 1.04 to 1.13]; p  0.001) and total AF
duration (HR: 1.06 [95% CI: 1.02 to 1.09]; p  0.001). In
multivariate analyses, only total AF duration (HR: 1.06
[95% CI: 1.02 to 1.09]; p  0.001) predicted arrhythmia
recurrence. Interestingly, when considering overall proce-
dures, PVI alone was no longer a significant parameter of
maintenance of long-term SR.
Patients with a total AF duration of 2 years had a
significantly higher success rate compared to other patients
(76.5% vs. 42.2% in SR, p  0.033) (Fig. 4). Patients with
Clinical, Ablation, and Outcome CharacteristicsBetween Acu e PVI Responder and AcuPVI Nonresponder by the Final Procedur
Table 3
Clinic l, Abla ion, and Outcome Characteristics
Between Acute PVI Responder and Acute
PVI Nonresponder by the Final Procedure
Parameter
Acute PVI
Responder
(n  105)
Acute PVI
Nonresponder
(n  97) p Value
Age, yrs 61 9 62 9 0.103
Male 83 (79) 77 (79) 0.953
Total AF duration, months 95 56 105 72 0.260
Total AF duration 2 yrs 8 (8) 9 (9) 0.671
Persistent AF duration, months 44 33 55 53 0.077
Amiodarone 55 (52) 60 (62) 0.174
Structural heart disease 17 (16) 15 (15) 0.888
LA diameter, mm 48 5 50 6 0.023
Hypertension 80 (76) 75 (77) 0.850
LVEF, % 60 6 60 7 0.834
CHADS2 score 1 1 1 1 0.572
Number of procedures 1.5 0.6 2.4 2.2 0.001
Procedure duration, min 223 66 238 64 0.107
Fluoroscopy duration, min 30 14 31 11 0.380
Complications 7 (7) 11 (11) 0.244
LAA isolation 0 (0) 10 (10) 0.001
Sinus rhythm 49 (47) 42 (43) 0.631
Values are mean  SD or n (%).
CHADS2  congestive heart failure, hypertension, age 75 years, diabetes mellitus, and prior
stroke or transient ischemic attack; LAA  left atrial appendage; other abbreviations as in Tables
1 and 2.a total AF duration of 2 years were almost 3 times morelikely to relapse after the last ablation (HR: 2.81 [95% CI:
1.04 to 7.63]; p  0.042).
Discussion
In this study, we found that: 1) circumferential PVI alone
was sufficient to restore SR in 24% of patients with LS-AF;
2) 5-year outcomes of LS-AF ablation remain mediocre
with a 45% multiple-procedure success rate; 3) AF regres-
sion is a common phenomenon found in 23% of patients;
and 4) persistent AF duration independently predicted
arrhythmia recurrences whereas acute PVI responders had a
reduced risk of relapse after the first ablation.
Pulmonary vein isolation in LS-AF. PVI is an effective
therapy for PAF patients, with success rates ranging from
57% to 80% at up to 5 years of follow-up (13–16). For
patients with LS-AF, there is conflicting evidence about the
long-term efficacy of PVI as the first-line ablative strategy
(17,18). In this study, using the sequential approach, PVI
was the first-line therapy for all patients. Additional ablative
strategies, for example, CFAEs, were only applied in PVI
nonresponders—if DC cardioversion failed after PVI or at
repeat ablation procedures when patients demonstrated no
PV reconnection.
In patients with LS-AF, observed5 years after ablation,
PVI alone was sufficient to restore and maintain SR in 24%
of patients. Regression of AF was noted in another 13% of
those patients, resulting in clinical improvement. This
finding suggests that the PVs and the antrum are important
substrates in patients with LS-AF. Interestingly, after the
first procedure, PVI alone was associated with a 46% relative
risk reduction in arrhythmia recurrence compared to acute
PVI nonresponders. Thus, successful DC cardioversion
after PVI may identify patients who have a less diseased LA.
For the majority of patients, repeat ablation and addi-
tional ablation strategies are required to maintain SR in 45%
of patients. Interestingly, success rates were similar between
patients undergoing PVI alone and PVI nonresponder
undergoing additional ablation strategies.
Procedural success was 37.6% after 1 or 2 procedures as
compared to 45% after as many as 5 procedures. More than
2 procedures were performed in 42 of 202 (22.3%) patients.
Although the patient number is not large enough to draw a
definite conclusion, these data indicate that the success rate
beyond the second procedure is reasonable. Importantly, in
patients undergoing 1 redo procedure, ablation strategies
in addition to PVI are required in the majority of patients,
and the incidence of ATs as the clinical arrhythmia in-
creases. The ATs are usually clinically worse tolerated but
more amenable to ablation than AF. The relatively high
incidence of redo procedures of LA linear lesions in this
study indicates the difficulty of obtaining durable complete
lines.
Complication rates in this study were in keeping with
previous publications (9). In PVI nonresponders, more
extensive ablation and more procedures were required. That
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patient, although it did not reach statistical significance.
Comparison with previous studies. Our study evaluated a
sequential approach to AF ablation while reserving addi-
tional ablative strategies for PVI nonresponders. That
makes this study unique and comparison with other studies
difficult. In all other studies, either PVI or additional
ablative strategies were performed, and DC cardioversion
after PVI was not attempted.
A recently published systematic review of the literature
evaluated the impact of ablation strategies on the outcomes
of LS-AF ablation (17). A total of 32 studies, including 4
randomized controlled trials, were analyzed. The meta-
analysis found that with respect to single-procedure and
drug-free success: 1) PVI is a superior approach compared
to PV ablation alone; 2) CFAE ablation alone is an inferior
strategy compared to PV ablation plus linear ablation at the
roof and mitral isthmus; and 3) CFAE ablation may or may
not provide incremental benefit when added to PVI (17).
The researchers concluded that, because of variation in
success within and between techniques, the optimal ablation
technique for LS-AF remains unclear.
A recent meta-analysis evaluated the efficacy of PVI
versus PVI plus CFAE ablation after a single procedure
without AADs (18); a total of 660 patients enrolled in 7
controlled trials were analyzed. The investigators found that
CFAE ablation in addition to PVI increases the rate of SR
Figure 4 Multiple Procedure Success for Patients With Total A
Kaplan-Meier event-free survival curves for patients with total atrial fibrillation (AF)
Plus sign () indicates censored. Arrhythmia-free survival was significantly higher
ATa  atrial tachyarrhythmia.maintenance in nonparoxysmal AF after a single procedure t(relative risk: 1.35 [95% CI: 1.04 to 1.75]; p  0.022), but
does not provide additional clinical benefit in PAF patients.
However, direct comparison of studies evaluating LS-AF
ablation is difficult, not only because of the different ablative
approaches but also because of heterogeneous patient pop-
ulations. For example, in several studies, patients with a
continuous AF duration of 12 months were included and
terms like “nonparoxysmal AF” or “chronic AF” used (17).
Despite the relatively conservative ablation strategy used
n this study, the single-procedure outcomes concur with
rior reports utilizing a more aggressive ablation protocol
19), and at first procedure, PVI as the sole ablative strategy
as associated with a lower risk for arrhythmia recurrence.
ermination of AF at the first procedure as well as at the
ast procedure did not influence outcomes. In this study, AF
ermination was only attempted in acute PVI nonre-
ponders; these patients may, therefore, represent a sub-
roup of patients with a more diseased LA, and thus explain
hy, in contrast to other studies, AF termination did not
nfluence outcomes.
A recent study demonstrated that the LAA can be trigger
ite of AF, and that LAA isolation may improve clinical
utcomes (20). However, the clinical impact and long-term
hromboembolic risk after LAA isolation is uncertain, and it
s important to balance the risks and benefits of additional
blation as they may increase the incidence of potential
omplications and adverse events such as LAA isolation and
ation <2 Years Versus >2 Years
on of 2 years (blue line) versus 2 years (red line) after the last procedure.
patients with AF duration 2 years (77% vs. 42% in sinus rhythm, p  0.033).F Dur
durati
amonghe occurrence of iatrogenic AT (2,19,21).
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of patients after the initial procedure (22). Since the PVs are
an important trigger and substrate in some patients with
LS-AF, achieving durable lesions may improve outcomes.
As long as durable isolation of the PVs cannot be estab-
lished with a single procedure, the final conclusion about the
value of PVI will remain uncertain.
There is still conflicting evidence about the efficacy of
additional ablation strategies used with PVI in patients with
LS-AF. CFAE ablation may improve outcomes but also
increases the risk of adverse events. To avoid overtreatment
of as many as a quarter of patients who can be successfully
treated with PVI only, we believe that PVI as the first-line
treatment is a reasonable approach, with further ablation
reserved for PVI nonresponder.
Time to arrhythmia recurrence. In the majority of pa-
tients arrhythmias recurred within the first year; however,
late recurrences (12 months) were noted in 15.3% of
patients. These results raise the question as to whether cure
for a heterogeneous and complex condition such as LS-AF
is feasible, or whether AF recurrence is only a matter of
time.
Three patients in whom OAC therapy was discontinued
because of apparently stable SR sustained thromboembolic
events. Although there is some evidence that OAC therapy
may be discontinued after AF ablation in patients at
moderate thromboembolic risk, data are sparse and nonran-
domized (23). Therefore, the indication for lifelong antico-
agulation therapy after ablation should be exclusively based
upon the CHA2DS2-VASc score (congestive heart failure,
ypertension, age 75 years, diabetes mellitus, and prior
troke/transient ischemic attack/thromboembolism, vascu-
ar disease, age 65 to 74, sex category female).
tudy limitations. Because of AF regression and symptom
mprovement in a significant number of patients, some
atients with recurrence did not undergo repeat ablation. A
igher rate of reablation may have resulted in improved
utcomes. Follow-up assessment of AF recurrence consisted
f 24-h Holter monitoring. As implantable loop recorders
r 7-day Holter monitoring were not used before ablation,
he longest continuous AF duration may have been over-
stimated, particularly in patients in whom infrequent
olter monitoring was performed. The overall success may,
herefore, have been overestimated. This study is descriptive
nd nonrandomized; its results require confirmation in
arger randomized controlled trials. During this study, AF
rocedures were restricted to patients with a body mass
ndex 35 kg/m2. Unfortunately, therefore, we were unable
o evaluate the clinical impact of body mass index.
onclusions
n patients with LS-AF, single procedure success is poor
uring 5-year follow-up. Repeat ablation and additional
blation strategies are often required to maintain SR in 45%.or patients with a total AF duration of 2 years, the
utcome appears to be favorable.
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